Revance announces FDA accepts sBLA for DAXXIFY

Revance Therapeutics announced that the U.S. FDA has accepted for review a supplemental Biologics License Application for DAXXIFY for injection for the treatment of cervical dystonia in adults, a chronic and debilitating neurologic condition affecting the muscles of the neck. Revance was provided a Prescription Drug User Fee Act date of August 19, 2023.